Drug design/development biotechnology

Guner, O.E. Pharmacophore Perception, Use and Development in Drug Design, lUL Biotechnologies Series, USA, 2000. 

Guner, O.F. (ed.), Pharmacophore Perception, Development and Use in Drug Design. IUL Biotechnology Series, Vol. 1. IUL,... 

Guner OF. Pharmacophore Perception, Development, and Use in Drug Design (Iul Biotechnology Series 2). (See Preface). International University Line La Jolla, CA, 2000. 

By 1991, more than 375 products had received orphan designation, and more than 40 orphan drugs were available In the US. Nine of the 15 biotechnology-derived drugs on the market have orphan drug status, as do 19 biotechnology-derived drugs under development. Some of these prod-... 

In contrast to rational drug design available chemical and combinatorial libraries are randomly screened against newly designed assays for identification of suitable leads for further chemical and biological developments. Major pharmaceutical and biotechnology companies routinely employ this approach in lead identification for new programs. The success of this approach depends on the size and quality of the respective chemical collections. 

Triazoles are an interesting class of heterocyclic units widely used in the discovery and modulation of drug candidates, development of new materials, supramolecular chemistry, design of new supported organocatalysts, and biotechnology area [55], Therefore, several elegant methods for the synthesis of this classic nitrogen heterocyclic compounds have been reported by 1,3-dipolar cycloaddition of azides with alkynes under thermal [56] conditions as well as copper catalysis. 

---